Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesArch Biopartners Inc

Arch Biopartners Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.85 CAD -0.03 ( 3.41%)
Last update at 2026-11-04T18:41:00Z
VOLUME
116041
Market Cap
31.25M

Momentum Score

…

Arch Biopartners Inc., together with its subsidiaries, engages in the development of novel drugs for acute kidney injury and organ damage in Canada. It focuses on developing its lead drug candidate LSALT Peptide, which is in Phase 2 trials to treat inflammation related acute kidney injury experienced by patients undergoing on-pump (bypass) cardiac surgery; and cilastatin to prevent toxin related acute kidney injury via dipeptidase-1. The company also develops CKD Platform, therapeutics targeting chronic kidney disease. Arch Biopartners Inc. is based in Toronto, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.81
Low
0.88
High
52 Week Price Range
0.46
Low
1.95
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Arch Biopartners Inc is a small, publicly listed life‑sciences company on the TSX Venture Exchange (ARCH.V); public disclosures are limited. Long‑term growth drivers appear to be clinical or product development milestones and strategic partnerships, which may benefit prospects if executed successfully.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.88
Dividend Yield
-
Revenue TTM
0.16M
Revenue Per Share
0.00
Gross Profit TTM
-0.45M
Debt / Equity
-0.91
ROE
-
Net Debt
2.49M
ROCE
31.99%
Diluted EPS TTM
-0.04

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Income before tax -1.55M -3.92M -3.59M -1.39M -1.17M
Net income -1.55M -3.92M -3.33M -1.39M -1.17M
Selling general administrative 1.15M 1.75M 0.38M 0.77M 0.96M
Selling and marketing expenses - - 0.01M 0.02M 0.04M
Gross profit - - -0.13M -0.50M -0.15M
Ebit - - -8.14M -1.08M -1.71M
Ebitda - - -5.24M -1.08M -0.89M
Depreciation and amortization - - 2.90M 0.31M 0.82M
Operating income -1.24M -3.56M -5.24M -1.08M -1.16M
Other operating expenses - - 5.24M 1.08M 0.89M
Interest expense 0.26M 0.39M 0.36M 0.31M 0.27M
Interest income 0.00M 0.00M 0.02M 0.00M -
Net interest income -0.26M -0.39M -0.34M -0.31M -0.27M
Income tax expense - - -0.26M -0.31M 0.04M
Total revenue 0.00M 0.00M 1.98M 0.96M 3.89M
Total operating expenses 1.24M 3.56M 5.24M 1.08M 0.89M
Cost of revenue - - 2.11M 1.47M 4.04M
Total other income expense net -0.05M 0.02M 1.65M -0.02M -0.00M
Net income from continuing ops -1.55M -3.92M -3.33M -1.39M -1.17M
Net income applicable to common shares - - - -1.41M -1.17M
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Total assets 0.10M 0.94M 1.17M 0.62M 2.67M
Other current assets - - 0.04M - -
Total liab 3.99M 5.28M 6.68M 5.09M 6.55M
Total stockholder equity -3.88M -4.35M -5.51M -4.47M -3.88M
Other current liab - - 0.17M - -
Common stock - - 15.88M 15.55M 14.76M
Capital stock 20.35M 17.42M 15.88M 15.55M 14.76M
Retained earnings -33.52M -31.97M -28.05M -24.72M -23.32M
Cash 0.00M 0.00M 0.83M 0.51M 0.45M
Total current liabilities 3.99M 5.28M 5.98M 2.78M 3.19M
Current deferred revenue - - 1.10M - -
Net debt 2.49M 2.77M 4.18M 3.91M 4.72M
Short term debt - - 4.31M - -
Short long term debt 2.50M 2.77M 4.31M 2.10M 1.80M
Short long term debt total - - 5.02M - -
Other stockholder equity - - 6.66M - -
Total current assets 0.10M 0.94M 1.17M 0.62M 2.67M
Net tangible assets - - - -4.47M -3.88M
Short term investments - - 0.82M - -
Net receivables 0.00M 0.72M 0.30M 0.09M 2.20M
Long term debt - - 0.70M 2.31M 3.36M
Accounts payable 1.04M 2.35M 0.39M 0.49M 0.96M
Non current assets total 0.00M 0.00M 0.00M 0.00M 0.00M
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Change to liabilities - - - 0.00M 0.00M
Net borrowings 0.00M 0.35M - -0.79M 1.73M
Total cash from financing activities 1.58M 1.50M 0.56M -0.42M 2.78M
Net income -1.55M -3.92M -3.33M -1.08M -1.17M
Change in cash -0.00M -0.83M 0.32M 0.06M -0.21M
Begin period cash flow 0.00M 0.83M 0.51M 0.45M 0.65M
End period cash flow 0.00M 0.00M 0.83M 0.51M 0.45M
Total cash from operating activities - - -0.23M -1.08M -2.98M
Issuance of capital stock 1.25M 1.36M 0.13M 0.37M 1.05M
Other cashflows from financing activities - - 1.43M -0.02M 2.15M
Change to netincome - - - 1.89M -1.81M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Stock based compensation - - 1.96M 0.02M 0.11M
Other non cash items - - 1.13M -0.02M -1.92M
Free cash flow -1.58M -2.33M -0.23M -1.08M -2.98M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ARCH
Arch Biopartners Inc		 -0.03
3.41%		 0.85 - - 197.68 6211.54 53.05 6970.51
SHRX
Sharp Therapeutics Corp.		 -
-%		 1.37 - - - 32.37 - -
NRX
NurExone Biologic Inc.		 -0.01
2.00%		 0.49 - 6.90 - 15.26 - -7.24
MIR
MedMira Inc		 -
-%		 0.06 - - 223.37 - 293.42 -80.03
TTI
Thiogenesis Therapeutics Corp.		 -
-%		 0.63 - - - 15.17 - -58.16

Profile*

Arch Biopartners Inc

Arch Biopartners Inc., together with its subsidiaries, engages in the development of novel drugs for acute kidney injury and organ damage in Canada. It focuses on developing its lead drug candidate LSALT Peptide, which is in Phase 2 trials to treat inflammation related acute kidney injury experienced by patients undergoing on-pump (bypass) cardiac surgery; and cilastatin to prevent toxin related acute kidney injury via dipeptidase-1. The company also develops CKD Platform, therapeutics targeting chronic kidney disease. Arch Biopartners Inc. is based in Toronto, Canada.

545 King Street West, Toronto, ON, Canada, M5V 1M1

647-428-7031

https://www.archbiopartners.com

Name Title Year Born
Mr. Richard Gabriel Muruve Co-Founder, CEO, Pres & Director 1971
Dr. Daniel Abraham Muruve Co-Founder, Chief Science Officer & Member of Scientific Advisory Board NA
Mr. Andrew Bishop CFA Acting CFO & Director 1966
Dr. Justin MacDonald Co-Founder & Principal Scientist NA
Dr. Paul Beck Co-Founder & Principal Scientist NA
Mr. Richard Gabriel Muruve Co-Founder, CEO, President & Director 1971
Dr. Daniel Abraham Muruve M.D. Co-Founder, Chief Science Officer & Member of Scientific Advisory Board NA
Mr. Andrew Bishop CFA CFO & Director 1966
Dr. Justin MacDonald Ph.D. Co-Founder & Principal Scientist NA
Mr. Aaron Benson Director of Communications NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.50
+15.05%
DSV
CAD 11.02
+14.55%
USA
CAD 4.29
+13.19%
NUAG
CAD 7.70
+12.90%
GMIN
CAD 43.79
+12.86%
DRUG
CAD 26.11
-29.58%
HUT
CAD 68.98
-22.41%
UCU
CAD 2.09
-14.34%
VET
CAD 14.87
-14.29%
PHX
CAD 10.96
-13.56%

Equity Sectors*

  • Basic Materials

    +5.46%

  • Communication Services

    +3.38%

  • Consumer Cyclical

    +3.11%

  • Consumer Defensive

    +1.35%

  • Energy

    -4.79%

  • Financial Services

    +2.66%

  • Healthcare

    -0.72%

  • Industrials

    -0.11%

  • Real Estate

    +1.84%

  • Technology

    +1.05%

  • Utilities

    +0.39%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…